---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-102265"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T18:49:19.298339+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Citius Pharmaceuticals Reports Productive FDA Type C Meeting for Mino-Lok Phase 3 Program

## Summary
- Citius Pharma held a constructive in-person Type C meeting with the FDA on November 25, 2024, regarding its Phase 3 Mino-Lok trial for catheter-related bloodstream infections.
- The FDA provided clear, actionable guidance on clinical efficacy and safety data, supporting a pathway to a future New Drug Application (NDA) submission.
- Chairman and CEO Leonard Mazur stated the Agency's comprehensive feedback provides a strong framework for completing remaining steps toward an NDA.
- Mino-Lok, if approved, could reduce healthcare costs and improve outcomes by salvaging central venous catheters instead of removing them.

## SEC filing metadata
- accession: 0001213900-24-102265
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024102265/0001213900-24-102265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024102265/ea0222478-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-102265
- JSON: https://secwatch.observer/filing/0001213900-24-102265.json
- Plain text: https://secwatch.observer/filing/0001213900-24-102265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.